Filing Flows › Arcadia Biosciences (RKDA) › Q2 2026 › vs Q2 2025
Arcadia Biosciences (RKDA) Q2 2026 vs Q2 2025 (year over year)
Arcadia Biosciences's revenue fell $12K (-0.8%) from $1.5M in Q2 2025 to $1.4M in Q2 2026.
Arcadia Biosciences, Q2 2026: revenue $1.4M (-0.8% year over year), operating margin -34.4%, net loss $6.3M, operating cash flow −$319K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.4M | $1.5M | −$12K | -0.8% |
| Net loss | $6.3M | $4.5M | $1.8M | +41% |
| Costs & expenses | $7.7M | $5.9M | $1.8M | +30% |
| Operating costs | $1.9M | $2.0M | −$17K | -0.9% |
| Interest & other, net | $5.8M | $4.0M | $1.8M | +46% |
| Operating cash sources | $6.3M | $4.4M | $1.8M | +41% |
| Share-based compensation | $14K | $86K | −$72K | -84% |
| Working capital & other | $5.9M | $2.3M | $3.6M | +155% |
| Cash used in operations | $319K | $2.0M | −$1.7M | -84% |
| Net loss absorbed | $6.3M | $4.5M | $1.8M | +41% |
Questions
How much did Arcadia Biosciences's revenue grow year over year in Q2 2026?
Arcadia Biosciences's revenue fell $12K (-0.8%) from $1.5M in Q2 2025 to $1.4M in Q2 2026.